Synthon’s Post

#BIO2026 opens in San Diego in ten days. 135 sessions across 18 focus areas. We have been deliberate about where we are spending our time. Five conversations we are there to hear: Whether AI in clinical operations has moved from pilot to production. The document generation question is the most measurable test of that transition. What biotechs are actually experiencing on the ground with FDA real-time oncology and rare disease trial frameworks. The policy positions are published. The operational reality at the site level is not. How sponsors and CROs are responding to site coordinator capacity as a hard ceiling on how many studies can activate. This is a documentation workflow problem dressed up as a staffing problem. Where the industry stands on EU CTR 536, FDA inspection priorities, and ICH harmonisation now that these are enforcement-stage obligations rather than future considerations. How the patient advocacy community is connecting accessible informed consent and plain language summaries to the patient access agenda. At BIO 2026 that connection gets the platform it deserves. We are attending to listen and have conversations that matter to the clinical trial operations community. If you are in San Diego and working on study startup, site activation, or regulatory documentation, we would welcome the conversation. #BIO2026 #ClinicalTrials #ClinicalResearch #StudyStartup #ProtocolIntelligence Full article: https://lnkd.in/g2M2NxXU

This content was funded and developed by Sanofi for scientific exchange and is intended for healthcare professionals only. 💡 Super excited to share this Interactive Infographic given the complexity of the underlying inflammation in patients with atopic dermatitis (AD), an increased understanding of the OX40 ligand pathway can improve insight into AD pathogenesis... https://lnkd.in/eJCi3wyk

There's a Haya Tx take over of BIO happening on Wednesday afternoon - invited to 3 separate panels - cardiovascular disease ❤️, regulatory genome 🧬, and AI/ML in deal making! #BIO2026

As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a series of efforts to regain ground on China’s surging early-stage clinical development capabilities. https://lnkd.in/e3Df9bAS

🚨 BREAKING News from Clival Database!| WEEK 3 | 16th June 2026 🚨 The clinical research and biotech landscape continues to evolve rapidly — and these latest developments are drawing major industry attention worldwide 🌍💊 🔹 Hillhurst Bio Doses First Patient in Phase 2a Trial of HBI-002 for Parkinson’s Disease. 🔹 Celldex Reports Long-Term Phase 2 Data for Barzolvolimab in Chronic Spontaneous Urticaria. 🚀 These breakthroughs highlight how innovation, advanced clinical strategies, and global expansion are reshaping the future of healthcare and patient outcomes. 🎥 Watch complete analysis & expert insights on our YouTube channel: 👉 https://lnkd.in/g655VA-J 📰 Explore more verified clinical and pharma updates anytime: 👉 https://clival.com/news 📊 Want deeper clinical intelligence, pipeline tracking, competitor benchmarking, and real-time pharma insights? 📅 Book a demo with Clival Database today: 👉 https://lnkd.in/dSdbxTJF 📡 Daily updates. Verified insights. Real-time research breakthroughs — only on Clival Database. 🌐 Visit: www.clival.com 📞 Toll-Free: 1800 4190 155 #Clival #ClivalDatabase #ClinicalResearch #PharmaNews #BiotechNews #ClinicalTrials #MedicalResearch #PharmaInnovation #BiotechInnovation #LifeSciences #DrugDevelopment #HealthcareInnovation #PharmaTrends #LifeScienceIntellipedia

🚨 Big news for global life sciences teams looking at the UK market! The UK has officially hit its ambitious 150-day target, slashing commercial clinical trial setup times down to an average of 122 days (a massive drop from 169 days last year). Thanks to the April 2026 MHRA reforms and streamlined unified reviews, the UK is fast-tracking its position as a global hub for clinical research. At MedLab Live 2027, our "Lab Operations & Regulations" track will be diving straight into how equipment innovators can capitalise on this faster pipeline. If your team is scaling up testing infrastructure to support this clinical trial boom, this is where you need to showcase your tech. Drop me a DM to see how we're connecting vendors directly with the clinical decision-makers scaling these trials. #MedLabLive #ClinicalTrials #LifeSciences #Genomics #PrecisionMedicine #MedTech

Today, we’re excited to share an important company building milestone. Within the Bio Studio environment at BioInnovation Institute (BII), SeeQ has evolved from a scientific project into an officially incorporated Danish ApS an important step in the transition from research-driven innovation toward an independent company. SeeQ is based on scientific research from Professor Mads Albertsen's group at Aalborg University and is developing a broad pathogen identification platform directly from blood samples, initially focused on patients suspected of sepsis and other high-risk infection settings. This progress has been supported by the funding, guidance, laboratory infrastructure, and venture-building support received through the Bio Studio and BioInnovation Institute ecosystem, helping SeeQ move from scientific project toward clinical impact and commercial development. Alongside incorporation, SeeQ has also reached early commercial milestones an encouraging signal of momentum as we continue building toward validation, impact, and disciplined company growth. This is a meaningful step in building a company focused on helping clinicians fight pathogens faster. We are grateful to everyone who has supported SeeQ so far and even more excited for what comes next as we continue building toward clinical validation, commercial readiness, and impact for patients and clinicians. The next phase starts now. #diagnostics #healthtech #biotech #translationalmedicine #clinicalinnovation

Clinical development exists for one reason: patients. Not publications. Not milestones. Not shareholder reports. In the latest episode of #TheEndTalks, our CEO Pedro Coelho sits down with Paolo Martini, Owner & Founder of Two Hundred Thousand Consulting LLC and one of biotech's most experienced leaders. After helping bring a COVID-19 vaccine to the world, Paolo saw his mission was complete. Then he encountered a therapy with the potential to save newborn lives that risked never reaching its full potential, and he felt compelled to step in. Because some missions are too important to walk away from. In this episode, they explore Paolo Martini's journey, how a life-changing event reshaped his perspective on life and work, and why he chose to dedicate the rest of his career to advancing science in service of patients. 🎧 Very soon on Spotify and YouTube. #Biotech #ClinicalTrials #Pharma #Healthcare #Patients

Just wrapped up an inspiring experience at the CPDD 88th Annual Scientific Meeting in Portland, OR — a valuable gathering of leaders advancing research and innovation in addictive disorders therapeutics development. The most rewarding part? Engaging in meaningful conversations with biopharma sponsors who are pushing the boundaries of what’s possible to address the unmet medical needs of patients suffering from substance use disorders. From discussing evolving clinical strategies to exploring new partnership opportunities, it’s clear that collaboration continues to be the driving force behind progress in our industry. Grateful for the opportunity to connect, learn, and exchange ideas with so many forward-thinking professionals. Looking forward to continuing these conversations and translating insights into impactful outcomes. #CPDD2026 #DrugDevelopment #Biopharma #ClinicalResearch #Partnerships #Innovation #LifeSciences #Networking #ScientificMeeting #Collaboration #Clinilabs #CROforCNS

Developing therapies for pediatric rare diseases requires navigating significant scientific and operational challenges. Early development decisions can have a lasting impact on study timelines, resource allocation, and regulatory strategy. In our on-demand webinar, 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗣𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗶𝗮𝗹𝘀 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗦𝗶𝘁𝗲 𝗡𝗲𝘁𝘄𝗼𝗿𝗸𝘀, experts discuss how combining model-informed drug development with specialized pediatric site networks can strengthen both study design and trial execution, including: • Using modeling and simulation to inform pediatric dose selection when clinical data is limited • Reducing early development uncertainty through quantitative approaches • Leveraging established pediatric site networks to improve feasibility and enrollment • Aligning scientific strategy with operational realities in rare disease research Watch the full recording here: #Allucent #BringingNewTherapiesToLight #RareDiseaseResearch #RarePediatricClinicalTrials #RareDiseaseCRO